Mega Lifesciences PCL (BKK:MEGA)

Market Cap	33.13B +15.2%
Revenue (ttm)	14.19B -7.7%
Net Income	1.91B -5.0%
EPS	2.19 -5.0%
Shares Out	871.87M
PE Ratio	17.33
Forward PE	14.21
Dividend	1.60 (4.21%)
Ex-Dividend Date	Mar 9, 2026

Volume	1,986,814
Average Volume	1,593,360
Open	36.00
Previous Close	38.00
Day's Range	34.25 - 36.25
52-Week Range	24.30 - 40.00
Beta	0.27
RSI	38.86
Earnings Date	Feb 24, 2026

About Mega Lifesciences PCL

Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods in Southeast Asia and Sub-Saharan Africa. The company operates in three segments: Brands, Distribution, and Original Equipment Manufacture (OEM). It provides various medicines for allergies; blood circulation and memory; bone and joint; liver and digestive; diabetics; eyes, heart, and skin care; pain, sl...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1982
• Employees: 900
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: MEGA

Financial Performance

In 2025, Mega Lifesciences PCL's revenue was 14.19 billion, a decrease of -7.74% compared to the previous year's 15.39 billion. Earnings were 1.91 billion, a decrease of -4.99%.